1-9 of 9
Gabriel Tremblay, DBA, MSc, BS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons

Gabriel Tremblay, DBA, MSc, BS, Patrick Daniele, Mike Dolph, MSc BHSc, Timothy J. Bell, Geoffrey Chan, MD, Andrew Brown, PhD, Joseph C Cappelleri, PhD MPH, MS
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-137641
Published: 2020
Journal Articles

Simulated Treatment Comparison (STC) of Human Mesenchymal Stromal Cells (Remestemcel-L, REM) and Ruxolitinib (RUX) for Steroid-Refractory Acute Graft-Versus-Host Disease (SR aGVHD) Pediatric Patients

Tracy Westley, MPH, Dimitrios Tomaras, MSc, Eric Strati, PharmD, Donna Skerrett, MD MS, Anna Forsythe, PharmD, MBA, MMSc, Gabriel Tremblay, DBA, MSc, BS
Journal: Blood
Blood (2019) 134 (Supplement_1): 4545.
https://doi.org/10.1182/blood-2019-131098
Published: 2019
Journal Articles

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Gabriel Tremblay, DBA, MSc, BS, Geoffrey Chan, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2709.
https://doi.org/10.1182/blood-2018-99-111931
Published: 2018
Journal Articles

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Geoffrey Chan, MD, Gabriel Tremblay, DBA, MSc, BS
Journal: Blood
Blood (2018) 132 (Supplement 1): 1429.
https://doi.org/10.1182/blood-2018-99-111971
Published: 2018
Journal Articles

Comparing Costs and Consequences of Eltrombopag Plus IST Versus IST Alone for First-Line Treatment in Severe Aplastic Anemia: Results from a Responder Analysis

Gabriel Tremblay, DBA, MSc, BS, Qayyim Said, PhD, Beilei Cai, PhD MA, Shan Ashton Garib, MA, Dimitrios Tomaras, MSc, Anna Forsythe, PharmD, MSc, MBA, Anuja Roy, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1041.
https://doi.org/10.1182/blood-2018-99-115138
Published: 2018
Journal Articles

Benefit-Risk Comparison in Patients with Immune Thrombocytopenia (ITP) Receiving Eltrombopag or Romiplostim: Real World Evidence (RWE) from 26 Hospital Institutions

Anna Forsythe, PharmD, MSc, MBA, Anuja Roy, PhD, Menaka Bhor, PhD, Alex Allepuz, MD MPH, Maria Do Socorro Oliveira Portella, MD MBA, Christina Kwon, BSc, MSc, PhD, Gabriel Tremblay, DBA, MSc, BS
Journal: Blood
Blood (2017) 130 (Supplement 1): 3409.
https://doi.org/10.1182/blood.V130.Suppl_1.3409.3409
Published: 2017
Journal Articles

A Canadian Cost-Effectiveness Analysis for the Treatment of Immune Thrombocytopenia: Assessing the Relative Value of with Eltrombopag Versus Romiplostim

Gabriel Tremblay, DBA, MSc, BS, Mike Dolph, MSc BHSc, Anuja Roy, PhD, Juliette Neyra, PharmD, Khalid El Ouagari, Anna Forsythe, PharmD, MSc, MBA
Journal: Blood
Blood (2017) 130 (Supplement 1): 3410.
https://doi.org/10.1182/blood.V130.Suppl_1.3410.3410
Published: 2017
Journal Articles

Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C Versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Gabriel Tremblay, DBA, MSc, BS, Bhakti Arondekar, BPharm, MBA, PhD, Geoffrey Chan, MD, Anastasiya Shor, PharmD, Anna Forsythe, PharmD, MSc, MBA, Su Yun, MD MPH
Journal: Blood
Blood (2017) 130 (Supplement 1): 5665.
https://doi.org/10.1182/blood.V130.Suppl_1.5665.5665
Published: 2017
Journal Articles

Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia

Gabriel Tremblay, DBA, MSc, BS, Menaka Bhor, PhD, Anuja Roy, PhD, Brian Elliott, MD, Mike Dolph, MSc BHSc, Anna Forsythe, PharmD, MSc, MBA, Andrew Briggs, DPhil
Journal: Blood
Blood (2017) 130 (Supplement 1): 2146.
https://doi.org/10.1182/blood.V130.Suppl_1.2146.2146
Published: 2017